Longas Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Out of Business

  • Employees
  • 6

Employees

  • Latest Deal Type
  • Out of Business

Longas General Information

Description

Developer of a DNA sequencing technology designed to improve resolution, accuracy and cost-effectiveness in genomics. The company's technology improves the performance of next-generation sequencing platforms, by increasing effective read lengths and converting short-read sequencers into virtual long-read sequencers, enabling healthcare professionals to use finished-quality genome assemblies with long DNA sequences at a fraction of the cost.

Contact Information

Website
www.longastech.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • PO Box 1168
  • Royal Exchange
  • Sydney, New South Wales 1225
  • Australia
Primary Industry
Biotechnology
Vertical(s)
HealthTech, Life Sciences
Corporate Office
  • PO Box 1168
  • Royal Exchange
  • Sydney, New South Wales 1225
  • Australia

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Longas Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 04-Feb-2025 Completed Out of Business
1. Later Stage VC 23-Jan-2021 Completed Generating Revenue
To view Longas’s complete valuation and funding history, request access »

Longas Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Class A
To view Longas’s complete cap table history, request access »

Longas Patents

  • 19

    Total Documents Applications and Grants

  • Total Patents Families

  • 10

    Granted

  • Pending

  • Expiring in next 12 mo

Longas Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201914064-D0 Method for determining a measure correlated to the probability that two mutated sequence reads derive from the same sequence comprising mutations Inactive 30-Sep-2019
WO-2021064365-A1 Method for determining a measure correlated to the probability that two mutated sequence reads derive from the same sequence comprising mutations Inactive 30-Sep-2019
GB-201907101-D0 Sequencing method Inactive 20-May-2019
EP-3710597-A1 Sequencing algorithm Active 13-Aug-2018
EP-3710597-B1 Sequencing algorithm Active 13-Aug-2018 C12Q1/6869
To view Longas’s complete patent history, request access »

Longas Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Longas FAQs

  • When was Longas founded?

    Longas was founded in 2015.

  • Where is Longas headquartered?

    Longas is headquartered in Sydney, Australia.

  • What is the size of Longas?

    Longas has 6 total employees.

  • What industry is Longas in?

    Longas’s primary industry is Biotechnology.

  • Is Longas a private or public company?

    Longas is a Private company.

  • What is Longas’s current revenue?

    The current revenue for Longas is .

  • How much funding has Longas raised over time?

    Longas has raised $3.06M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process